Anti-Human S1P Recombinant Antibody (Sonepcizumab) (CAT#: TAB-H64)

Figure 1 Growth curves depicting average tumor volume of 786-O derived tumors from mice treated with vehicle gavage, sphingomab (10 mg/kg), sphingomab (50 mg/kg).

Vehicle-treated tumors increased in volume more quickly than those treated with sphingomab. Average time to 75% volume was 8.5 days in the control versus 14.7 and 17.5 days in the 10 and 50 mg/kg groups, respectively.

Zhang, L., Wang, X., Bullock, A. J., Callea, M., Shah, H., Song, J., ... & Atkins, M. B. (2015). Anti-S1P antibody as a novel therapeutic strategy for VEGFR TKI-resistant renal cancer. Clinical cancer research, 21(8), 1925-1934.

Figure 2 sphingomab inhibits 786-O derived tumors growth.

Tumor growth in the A498 model is shown; vehicle-treated tumors increased in volume more quickly than those treated with sphingomab.

Zhang, L., Wang, X., Bullock, A. J., Callea, M., Shah, H., Song, J., ... & Atkins, M. B. (2015). Anti-S1P antibody as a novel therapeutic strategy for VEGFR TKI-resistant renal cancer. Clinical cancer research, 21(8), 1925-1934.

Figure 3 Thermostability comparison of the humanized antibody variants.

The thermostability of the variants was determined by measuring its S1P-binding affi nity by direct binding ELISA. Each antibody (25 μg/ml in PBS) was incubated at 60, 62, 64, 66, 68, 70, and 72, up to 78°C for 10 min and then removed insoluble material by centrifugation for 1 min at 13,000 rpm.

O'Brien, N., Jones, S. T., Williams, D. G., Cunningham, H. B., Moreno, K., Visentin, B., ... & Matteo, R. (2009). Production and characterization of monoclonal anti-sphingosine-1-phosphate antibodies. Journal of lipid research, 50(11), 2245-2257.

Figure 4 Antibody inhibition of IL-8 release in response to S1P.

Cell conditioned media from SKOV3 human ovarian cancer cells were tested for CXCL8/IL-8 levels after 18 h of incubation with 5 μM S1P in the presence or absence of increasing concentrations of either LT1009 or LT1002 (2–2,500 μg/ml).

O'Brien, N., Jones, S. T., Williams, D. G., Cunningham, H. B., Moreno, K., Visentin, B., ... & Matteo, R. (2009). Production and characterization of monoclonal anti-sphingosine-1-phosphate antibodies. Journal of lipid research, 50(11), 2245-2257.

Figure 1 Recombinant Anti-S1P Antibody (TAB-H64) in SDS-PAGE

SDS-PAGE analysis of TAB-H64 in non-reduced (Lane 1) and reduced (Lane 2) conditions.

Figure 2 Recombinant Anti-S1P Antibody (TAB-H64) in HPLC

HPLC analysis of TAB-H64 shows the purity is>95%.